Yoda Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	347.29	569.11	34.77	19.2
Short-Term Investments	102.64	54.74	296.97	-
Cash & Short-Term Investments	449.92	623.85	331.74	19.2
Cash Growth	2242.99%	88.06%	1627.52%	-
Other Receivables	1.64	2.31	2.34	0.07
Receivables	1.64	2.31	2.34	0.07
Prepaid Expenses	8.66	4.28	10.71	0.81
Other Current Assets	0.34	0	-	-
Total Current Assets	460.57	630.45	344.78	20.08
Property, Plant & Equipment	3.88	4.68	1.49	0.44
Other Intangible Assets	8	9.25	9.25	9.84
Other Long-Term Assets	0.77	0.08	3.04	0.01
Total Assets	473.21	644.45	358.57	30.36
Accrued Expenses	23.5	13.21	22.02	2.49
Current Portion of Long-Term Debt	-	-	-	9.23
Current Portion of Leases	0.8	0.79	-	-
Other Current Liabilities	4.54	3.55	0.81	0.89
Total Current Liabilities	28.83	17.55	22.83	12.6
Long-Term Leases	0.41	0.81	-	-
Total Liabilities	29.24	18.36	22.83	12.6
Common Stock	793.88	773.88	0.19	0.24
Additional Paid-In Capital	233.45	194.45	501.83	112.86
Retained Earnings	-598.88	-371.88	-179.68	-94.36
Treasury Stock	-	-	-	-0.47
Comprehensive Income & Other	15.52	29.64	12.75	-0.67
Total Common Equity	443.97	626.09	335.09	17.6
Shareholders' Equity	443.97	626.09	335.74	17.76
Total Liabilities & Equity	473.21	644.45	358.57	30.36
Total Debt	1.21	1.6	-	9.23
Net Cash (Debt)	448.71	622.25	331.74	9.97
Net Cash Growth	4398.84%	87.57%	3226.00%	-
Net Cash Per Share	6.18	14.58	27.86	0.85
Filing Date Shares Outstanding	79.39	77.39	79.39	11.67
Total Common Shares Outstanding	79.39	77.39	11.98	11.67
Working Capital	431.73	612.9	321.95	7.48
Book Value Per Share	5.59	8.09	27.96	1.51
Tangible Book Value	435.97	616.85	325.84	7.76
Tangible Book Value Per Share	5.49	7.97	27.19	0.67
Machinery	3.92	3.77	2.06	0.76

Source: S&P Global Market Intelligence. Standard template. Financial Sources.